The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Platinum re-treatment as a second-line option for clinically and molecularly defined platinum-sensitive metastatic non-small cell lung cancer (NSCLC).
L. H. de Lima Araujo
No relevant relationships to disclose
S. B. S. P. Terra
No relevant relationships to disclose
A. R. C. Pires
No relevant relationships to disclose
I. A. Small
No relevant relationships to disclose
A. C. D. Melo
No relevant relationships to disclose
C. Sternberg
No relevant relationships to disclose
C. G. M. Ferreira
No relevant relationships to disclose